In fact, key metabolic features of T2D, such as hyperinsulinemia, chronic low‐grade inflammation, and impaired glucose homeostasis, may modulate the functional effects of CDKN1B and TCF7L2 variants. This evidence concerns the gene TCF7L2 and Hyperinsulinemia.